@article{5a5f7977dded465ba7e3040a640b5abb,
title = "Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland",
keywords = "Biological therapies, Certolizumab pegol, Disease-modifying antirheumatic drugs, Health economics, Health policies, Rheumatoid arthritis, Rheumatology, MODIFYING ANTIRHEUMATIC DRUGS, 5-YEAR FOLLOW-UP, QUALITY-OF-LIFE, COST-EFFECTIVENESS, EULAR RECOMMENDATIONS, PRODUCTIVITY COSTS, DISEASE-ACTIVITY, 2013 UPDATE, REGISTER, BURDEN, 3121 General medicine, internal medicine and other clinical medicine, 317 Pharmacy",
author = "Erkki Soini and Christian Asseburg and Maarit Taiha and Kari Puolakka and Oana Purcaru and Riitta Luosuj{\"a}rvi",
year = "2017",
month = oct,
doi = "10.1007/s12325-017-0614-8",
language = "English",
volume = "34",
pages = "2316--2332",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Adis",
number = "10",
}